Rijavec Erika, Biello Federica, Genova Carlo, Barletta Giulia, Maggioni Claudia, Dal Bello Maria Giovanna, Coco Simona, Truini Anna, Vanni Irene, Alama Angela, Beltramini Sabrina, Grassi Maria Attilia, Boccardo Francesco, Grossi Francesco
IRCCS AOU San Martino IST- Istituto Nazionale per la Ricerca sul Cancro, UOS Tumori Polmonari , Largo Rosanna Benzi n° 10, 16132 Genova , Italy +39 0105600665; +39 0105600795;
Expert Opin Biol Ther. 2015;15(9):1371-9. doi: 10.1517/14712598.2015.1073709. Epub 2015 Jul 27.
Immunotherapy has become a promising approach for the treatment of NSCLC. In order to stimulate the host immune system against tumour antigens, several cancer vaccines have been generated and evaluated. Belagenpumatucel-L is a whole tumour cell vaccine expressing the antisense strand of the TGF-β2 gene.
The purpose of this article is to review the most relevant findings of clinical trials testing belagenpumatucel-L in advanced NSCLC patients.
Although the Phase III trial investigating belagenpumatucel-L in stage III/IV patients did not meet its primary end point, a survival benefit was observed in several subgroups of patients. Further studies are needed in order to select patients who may benefit from this vaccine.
免疫疗法已成为治疗非小细胞肺癌（NSCLC）的一种有前景的方法。为了刺激宿主免疫系统对抗肿瘤抗原，已经研发并评估了几种癌症疫苗。Belagenpumatucel-L是一种表达转化生长因子-β2（TGF-β2）基因反义链的全肿瘤细胞疫苗。
本文旨在综述在晚期NSCLC患者中测试Belagenpumatucel-L的临床试验的最相关研究结果。
尽管在III/IV期患者中研究Belagenpumatucel-L的III期试验未达到其主要终点，但在几个患者亚组中观察到了生存获益。为了选择可能从这种疫苗中获益的患者，还需要进一步研究。
